Takeda initiates continuation study of Zasocitinib for Psoriatic Arthritis
Takeda is conducting a continuation study of Zasocitinib in adults with Psoriatic Arthritis to assess long-term safety and efficacy.
Asset / Drug
Drug and asset intelligence for Zasocitinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.